Warner Chilcott to lay off 88 in NJ; NICE rethinks new MabThera use; GSK puts €2.2 million behind Greek expansion;

@FiercePharma: Funnily enough, we publish Top 15 Drug Launch Superstars, and 1000s click thru to last year's Top 10 Launch Disasters. | Follow @FiercePharma

@CarlyHFierce: ICYMI yesterday: Acino agrees to $439M takeover offer from private equity firms. More | Follow @CarlyHFierce

> On the heels of regulatory approval for its takeover by Actavis ($ACT), Warner Chilcott said it would lay off 88 workers from a New Jersey facility. Report

> The U.K.'s cost-effectiveness watchdog is reconsidering its previous position against Roche's ($RHHBY) MabThera as a treatment for a rare autoimmune disorder. Report

> GlaxoSmithKline ($GSK) said it would invest €2.2 million in Greece to boost packaging capacity for four over-the-counter products. Report

> Forest Laboratories ($FRX) filed another lawsuit against First Time US Generics over the latter's plans to sell a copy of the drugmaker's product Savella. Report

> Three death row inmates sued the state of Texas, claiming that officials plan to experiment with new execution drugs that they obtained from drugmakers under false pretenses. Report

Medical Device News

@FierceMedDev: Lensar hauls in $87M for laser eye surgery tech. News | Follow @FierceMedDev

@MarkHFierce: FierceDiagnostics has another great crop of stories for you. Check it out | Follow @MarkHFierce

@MichaelGFierce: ICYMI: Oral peptide delivery biz Enteris lands Nordic partnership. More from FierceDrugDelivery | Follow @MichaelGFierce

> Covidien CEO: It's about how, not how much, you spend on R&D. Report

> With Mako set for sale, Wright may be next orthopedic M&A target. Story

> Report: French regulators acted too slowly on PIP breast implant scandal. Item

Biotech News

@FierceBiotech: ICYMI: Top 15 highest paid biopharma R&D chiefs. Special report | Follow @FierceBiotech

@JohnCFierce: The turnaround plan: stay put, target drugs, more deals--John Reed sets out on a long-distance run at Roche's pRED. Feature | Follow @JohnCFierce

@DamianFierce: Updated story on Frazier's $377M new fund with comments from General Partner Jamie Topper. ICYMI yesterday | Follow @DamianFierce

@EmilyMFierce: NIH Feels Multiplying Effects of Government Shutdown. Article from Scientific American | Follow @EmilyMFierce

> Analyst: More Lilly R&D failures likely to trigger 'savage cost cuts.' More

> Cancer biotech upstart nabs $33M A round for R&D work, Array collaboration. Story

> J&J makes an R&D splash with $42M venture play, biotech collaborations. Report

> Shutdown halts NIH drug trials as researchers hit brakes on preclinical research. Article

Vaccines News

> NIH expands vaccine clinical trial network. Item

> CDC reports across-the-board rises in flu vaccine uptake. Report

> Researchers highlight knowledge gaps hindering cancer vaccines. Story

> Vaccines spared as Merck takes ax to R&D. More

> Government shutdown forces CDC to halt seasonal flu program. Article

Pharma Manufacturing News

@EricPFierce: Hospira faces more vial problems. FDA and co. says glass strands pose potential health threat. More | Follow @EricPFierce

> Ranbaxy denies FDA issues will lead to layoffs. Item

> SCM offers 'blank canvas' to sterile injectable clients. Story

> FDA threatens drugmaker with ban for not paying user fee. Article

> CML, AAIPharma join forces to create CMC specialist. More

And Finally... Belgium's UCB backed a U.K.government plan to invest £400 million into science and engineering training at English universities, but it asked for more innovation-friendly moves. Report

Suggested Articles

Download our solutions overview to discover how CoverMyMeds can make a difference for your brand.

In a bladder cancer field chock-full of checkpoint inhibitors, Pfizer and Merck KGaA’s Bavencio has a chance to get ahead thanks to new data.

The FDA backtracked on its earlier testing and found NDMA contamination in the extended release formulation of certain generic versions of metformin.